Tarsus Pharmaceuticals, Inc.
TARSNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $451.4M | $183.0M | $17.4M | $25.8M | $57.0M | $0 |
| Operating income | −$71.0M | −$120.6M | −$143.2M | −$62.7M | −$12.2M | −$27.0M |
| Net income | −$66.4M | −$115.6M | −$135.9M | −$62.1M | −$13.8M | −$26.8M |
| Total assets | $562.2M | $377.0M | $265.5M | $227.9M | $178.9M | $172.0M |
| Total liabilities | $218.7M | $152.5M | $68.5M | $35.0M | $12.2M | $6.0M |
| Equity | $343.4M | $224.5M | $197.0M | $192.9M | $166.7M | $166.0M |
| EPS (diluted) | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 | $-4.32 |
| Shares out. | 38.4M | 34.2M | 26.7M | 20.7M | 20.5M | 20.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −15.7%
- Net margin
- −14.7%
- Return on equity
- −19.3%
- Return on assets
- −11.8%
- Return on capital (ROCE)
- −16.6%
- Liabilities / assets
- 38.9%
- Debt / equity
- 0.64×
- Book value / share
- $8.95
- Revenue growth (YoY)
- 146.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 2.84safe
- Accruals / assets
- −9.6%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- XDEMVYJul 24, 2023
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Enrolling By Invitationreadout ~2026-12-31Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
- Phase 2Recruitingreadout ~2027-10A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Janus Henderson Group PlcPassive (13G)May 15, 2026
- Deep Track Capital, LpPassive (13G)May 15, 2026
- Prudential Financial IncPassive (13G)May 8, 2026
- Jennison Associates LlcPassive (13G)May 6, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Tang Capital Management LlcPassive (13G)Feb 17, 2026
- Rtw Investments, LpPassive (13G)Aug 14, 2025
- Morgan StanleyPassive (13G)May 7, 2025
- Blackrock, Inc.Passive (13G)Apr 24, 2025
- Cowen Financial Products LlcPassive (13G)Feb 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Pyott David E IDirector | Apr 24, 2026 | Option exercise | 1,383 | — |
| Neervannan SeshadriOfficer — Chief Operating Officer | Mar 20, 2026 | Sell | 2,989 | $66.75 |
| Whitfield Dianne C.Officer — Chief Human Resources Officer | Mar 17, 2026 | Sell | 4,029 | $69.42 |
| Wahl BryanOfficer — General Counsel | Mar 17, 2026 | Sell | 4,084 | $69.42 |
| Neervannan SeshadriOfficer — Chief Operating Officer | Mar 17, 2026 | Sell | 3,125 | $69.42 |
| Mottiwala AzizOfficer — Chief Commercial Officer | Mar 17, 2026 | Sell | 4,286 | $69.42 |
| Lin Elizabeth YeuOfficer — Chief Medical Officer | Mar 17, 2026 | Sell | 375 | $69.42 |
| Farrow Jeffrey SOfficer — See Remarks | Mar 17, 2026 | Sell | 2,111 | $69.42 |
| Azamian Bobak R.Officer — President/CEO and Board Chair | Mar 17, 2026 | Sell | 10,972 | $69.42 |
| Link William J PhdDirector | Mar 16, 2026 | Sell | 3,629 | $68.09 |
| Whitfield Dianne C.Officer — Chief Human Resources Officer | Mar 15, 2026 | Option exercise | 23,909 | — |
| Wahl BryanOfficer — General Counsel | Mar 15, 2026 | Option exercise | 24,236 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.9M | 5.7 | +1.8% |
| Apr 30, 2026 | 4.8M | 7.5 | +5.7% |
| Apr 15, 2026 | 4.6M | 13.2 | -0.4% |
| Mar 31, 2026 | 4.6M | 9.0 | -8.9% |
| Mar 13, 2026 | 5.0M | 10.1 | -5.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 6, 2026
- Results of operationsFeb 23, 2026
- Director / officer changeFeb 18, 2026
- Regulation FD disclosureJan 12, 2026
- Results of operationsNov 4, 2025
- Results of operationsAug 6, 2025
- Shareholder voteJun 18, 2025
- Results of operationsMay 1, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 8, 2026
- SCHEDULE 13G/AMay 6, 2026
- 10-QMay 6, 2026
- 8-KMay 6, 2026
- 4FORM 4Apr 28, 2026
- ARSApr 28, 2026
- DEFA14AApr 28, 2026
- DEF 14AApr 28, 2026
- SCHEDULE 13G/AMar 27, 2026
- 4FORM 4Mar 24, 2026
- 144Mar 20, 2026
- 4FORM 4Mar 19, 2026
- 4FORM 4Mar 19, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.